This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Eli Lilly and Company. This research review is compiled from publicly available peer-reviewed literature for educational purposes only.
Retatrutide (LY3437943) is an investigational acylated peptide engineered to co-activate three metabolic receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its tri-receptor profile builds on established dual-agonist pharmacology by incorporating glucagon receptor agonism, which introduces thermogenic and lipolytic mechanisms not present in earlier-generation incretin compounds. Phase 1b and Phase 2 data reported dose-dependent pharmacological activity with weight reductions of up to 24.2% at 48 weeks. Phase 3 TRIUMPH program results, reported in late 2025 and 2026, documented weight reductions of up to 25.0% at 80 weeks in the TRIUMPH-1 obesity trial and up to 28.7% at 68 weeks in the TRIUMPH-4 osteoarthritis trial. Clinical trials have reported substantial reductions in body weight; however, retatrutide remains an investigational compound and long-term safety and regulatory outcomes remain under evaluation. All referenced studies involve human clinical trial participants; in vitro applications of the compound are for mechanistic receptor pharmacology research.
1. Background
1.1 The Incretin System
Incretin hormones are a class of gut-derived peptides released in response to nutrient ingestion that potentiate glucose-stimulated insulin secretion from pancreatic beta cells. The two primary incretins are glucagon-like peptide-1 (GLP-1), secreted by intestinal L-cells, and glucose-dependent insulinotropic polypeptide (GIP), secreted by intestinal K-cells. Together, they account for the majority of the postprandial insulin response in healthy individuals — a phenomenon known as the incretin effect [1].
In addition to their insulinotropic effects, GLP-1 and GIP exert a range of metabolic actions relevant to appetite regulation, gastric motility, adipose tissue signaling, and central nervous system satiety pathways. These pleiotropic effects have made incretin-related receptors a major target in metabolic research over the past two decades.
Glucagon, secreted by pancreatic alpha cells, is classically understood as a counter-regulatory hormone that raises blood glucose through hepatic glycogenolysis and gluconeogenesis. However, preclinical research has demonstrated that glucagon receptor (GCGR) agonism also drives energy expenditure, promotes lipolysis in adipose tissue, and activates thermogenic pathways — effects that, in the context of simultaneous GLP-1R and GIPR agonism, may be metabolically favorable. The long-term physiological consequences of chronic glucagon receptor activation remain incompletely characterized and represent an active area of ongoing research.
1.2 From Mono- to Triple-Agonism
The first-generation incretin-based compounds were monoagonists targeting GLP-1R exclusively (e.g., exenatide, liraglutide, semaglutide). The approval of tirzepatide — a dual GIP/GLP-1 co-agonist — in 2022 demonstrated that simultaneous engagement of multiple incretin receptors could meaningfully amplify metabolic research outcomes relative to GLP-1 monoagonism alone [2].
Retatrutide represents the next step in this progression: a triple co-agonist designed to engage GIPR, GLP-1R, and GCGR simultaneously. The addition of glucagon receptor agonism introduces mechanisms not accessible through incretin pathways alone, particularly relating to hepatic energy flux and thermogenesis.
1.3 Development of Retatrutide
Retatrutide (internal code LY3437943) was developed by Eli Lilly and Company. Wholesale Peps is not affiliated with, endorsed by, or associated with Eli Lilly and Company. It is an acylated peptide with a C20 fatty acid chain designed to extend circulatory half-life through reversible albumin binding, enabling weekly subcutaneous dosing. Its backbone incorporates pharmacophore elements derived from GIP, GLP-1, and glucagon peptide sequences, with modifications to confer balanced potency across all three receptor targets [3].
The compound entered clinical evaluation in Phase 1 studies beginning approximately 2020, with Phase 1b data published in The Lancet in 2022 and landmark Phase 2 obesity data published in The New England Journal of Medicine in 2023. Phase 3 results from the TRIUMPH program followed in late 2025 (TRIUMPH-4) and 2026 (TRIUMPH-1), establishing registration-quality efficacy and safety data.
2. Molecular Structure and Pharmacokinetics
Retatrutide is a 36-amino acid acylated peptide. Its structure differs from first-generation GLP-1 agonists in several key respects:
- C20 fatty acid acylation: A 20-carbon fatty acid chain is attached via a gamma-glutamic acid linker, enabling high-affinity albumin binding. Albumin binding extends the effective half-life to approximately 6 days, supporting once-weekly subcutaneous dosing — compared to once-daily dosing for liraglutide or the modified C18 diacid acylation used in semaglutide [3].
- Triple pharmacophore integration: Rather than stacking three individual peptide sequences, the backbone is engineered as a single contiguous sequence with overlapping pharmacophore regions capable of engaging all three receptors.
- Balanced receptor potency: Preclinical receptor binding assays indicate approximately equal sub-nanomolar potency at GLP-1R and GIPR, with slightly lower but pharmacologically meaningful potency at GCGR. This is in contrast to earlier triple-agonist concepts that exhibited significant receptor potency imbalances.
Following subcutaneous injection, retatrutide reaches peak plasma concentration (Tmax) at approximately 24–72 hours post-dose, with a terminal half-life supporting weekly administration. Clearance is primarily proteolytic, with minimal renal clearance expected based on molecular size.
3. Mechanism of Action
3.1 GLP-1 Receptor Agonism
Activation of GLP-1R by retatrutide follows the same mechanistic pathway as established GLP-1 monoagonists. GLP-1R is a class B G-protein-coupled receptor (GPCR) that signals primarily through the Gsα subunit, driving adenylyl cyclase activation and cAMP accumulation in target cells. In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2), which potentiate glucose-stimulated insulin exocytosis in a strictly glucose-dependent manner — meaning GLP-1R agonism does not drive insulin secretion in the absence of elevated blood glucose [1].
Beyond the pancreas, GLP-1R is expressed in the hypothalamic arcuate nucleus, nucleus tractus solitarius (NTS), and vagal afferent neurons, where its activation reduces food intake by modulating hunger and satiety signaling. Slowing of gastric emptying via GLP-1R further contributes to reduced caloric intake by prolonging postprandial fullness.
3.2 GIP Receptor Agonism
The GIP receptor (GIPR) also signals through Gsα/cAMP pathways and, like GLP-1R, potentiates glucose-stimulated insulin secretion. In the context of a co-agonist, GIPR activation provides additive and potentially synergistic insulinotropic signaling with GLP-1R, augmenting the overall insulin secretory response [2].
Beyond the pancreas, GIPR is expressed in adipose tissue, bone, brain, and gastrointestinal epithelium. Adipose GIPR signaling has been linked to lipid uptake modulation and may play a role in the redistribution of energy substrate between adipose depots. Notably, GIPR agonism at the CNS level has been proposed as a mechanism for attenuating the nausea associated with GLP-1R agonism, though the precise nature of this interaction remains under investigation.
3.3 Glucagon Receptor Agonism — The Key Differentiator
The addition of GCGR agonism is the mechanistic feature that distinguishes retatrutide from all prior incretin-based compounds. Classically, glucagon raises blood glucose through hepatic glycogenolysis and gluconeogenesis — an effect that would appear counterproductive in a metabolic research context. However, when GCGR agonism is delivered in the setting of GLP-1R co-activation (which simultaneously suppresses glucagon-driven hepatic glucose output and potentiates insulin secretion), the net glycemic effect of GCGR activation may be largely neutralized, while the non-glycemic effects of GCGR agonism persist [3].
These non-glycemic GCGR effects include:
- Thermogenesis: GCGR activation has been reported in preclinical models to increase brown adipose tissue (BAT) thermogenic activity and overall energy expenditure, potentially through sympathetic nervous system modulation and direct adipocyte signaling.
- Lipolysis: Glucagon receptor signaling promotes lipolysis in adipose tissue via PKA-mediated activation of hormone-sensitive lipase, releasing free fatty acids for β-oxidation.
- Hepatic fat metabolism: GCGR activation promotes hepatic fatty acid oxidation and may reduce hepatic steatosis in preclinical liver disease models.
- Central appetite regulation: GCGR is expressed in the hypothalamus and brainstem, where its activation may contribute to satiety signaling independently of the incretin pathways.
3.4 Receptor Signaling Synergy
An important area of ongoing research is whether the three receptor targets in retatrutide act independently or exhibit pharmacodynamic synergy. Preclinical co-activation studies suggest that combined GIPR/GLP-1R engagement amplifies cAMP signaling beyond what either receptor achieves alone, potentially due to receptor heterodimerization or convergent Gsα signaling at shared downstream effectors. The contribution of GCGR to this synergy is less well-characterized and represents an active area of mechanistic investigation.
4. Receptor Binding Profile
The following table summarizes the approximate receptor potency (EC50) profile of retatrutide versus related incretin compounds based on preclinical receptor activation assays. Values reflect in vitro cAMP assay data and should not be extrapolated directly to in vivo potency rankings.
| Compound | GLP-1R | GIPR | GCGR | Class |
|---|---|---|---|---|
| Semaglutide | ~0.4 nM | — | — | GLP-1R Monoagonist |
| Tirzepatide | ~1 nM | ~0.4 nM | — | GIP/GLP-1 Dual Agonist |
| Retatrutide | ~1 nM | ~0.5 nM | ~2 nM | GIP/GLP-1/GCG Triple Agonist |
Retatrutide’s GCGR potency (~2 nM) is lower than its GLP-1R and GIPR potency, which researchers have proposed may be intentional — providing sufficient GCGR engagement to elicit thermogenic and lipolytic signaling while avoiding the degree of glucagon receptor activation that would produce clinically meaningful hyperglycemia in fasting states [3].
5. Key Research Findings
5.1 Phase 1b Trial — Urva et al., 2022
The first significant human pharmacology data for retatrutide were published in The Lancet by Urva and colleagues in 2022 [4]. This Phase 1b multiple-ascending dose (MAD) trial enrolled adults with type 2 diabetes (T2D) across multiple centers.
| Parameter | Detail |
|---|---|
| Population | Adults with type 2 diabetes, BMI 23–50 kg/m² |
| Design | Multicentre, double-blind, placebo-controlled, randomised MAD |
| Duration | 12-week treatment period |
| Doses | 0.5 mg, 1 mg, 3 mg, 6 mg (weekly subcutaneous) |
| Primary endpoint | Safety, tolerability, and pharmacokinetics |
| Secondary | HbA1c change, body weight change, fasting glucose |
Retatrutide demonstrated dose-dependent reductions in HbA1c and body weight across all active dose cohorts. At the 6 mg/week dose, statistically significant reductions in both HbA1c and body weight were observed relative to placebo at 12 weeks. Pharmacokinetic parameters were consistent with the anticipated albumin-binding half-life, supporting weekly dosing. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), dose-dependent in frequency, and generally transient. No severe hypoglycemia was reported [4].
5.2 Phase 2 Trial — Jastreboff et al., 2023
The pivotal Phase 2 data were published in The New England Journal of Medicine by Jastreboff and colleagues in 2023 [5]. This randomised, double-blind, placebo-controlled trial enrolled 338 adults with obesity (without diabetes) and evaluated multiple doses of retatrutide over 24 weeks (primary endpoint) with a 24-week extension period (48 weeks total).
| Parameter | Detail |
|---|---|
| Population | Adults with obesity (BMI ≥27 + comorbidity or BMI ≥30), without diabetes |
| Design | Double-blind, placebo-controlled, randomised |
| n | 338 participants |
| Doses | 1 mg, 4 mg, 8 mg, 12 mg (weekly subcutaneous) |
| Primary endpoint | % change in body weight at 24 weeks |
| Extension | 24-week additional follow-up (48 weeks total) |
5.3 Weight Loss Outcomes
The Phase 2 trial demonstrated substantial dose-dependent reductions in body weight across all active dose groups. The 12 mg/week cohort achieved the largest effects, with weight loss continuing to accumulate over the full 48-week treatment period rather than plateauing at 24 weeks — suggesting that the pharmacological ceiling of the compound may not have been reached within the trial duration [5].
Approximate percent body weight change from baseline at 24 weeks by dose group. Values are estimated from Jastreboff et al., 2023 [5]. Verify exact figures from the source publication. All participants had obesity without diabetes.
| Dose Group | ~24-Week Body Weight Change | ~48-Week Body Weight Change | vs. Placebo (24 wk) |
|---|---|---|---|
| Placebo | −1.6% | −2.1% | — |
| 1 mg / week | −7.9% | −10.4% | −6.3 pp |
| 4 mg / week | −12.9% | −17.3% | −11.3 pp |
| 8 mg / week | −14.9% | −22.8% | −13.3 pp |
| 12 mg / week | −17.5% | −24.2% | −15.9 pp |
The 48-week data from the extension period showed continued weight reduction across all dose cohorts, with the 12 mg group achieving approximately 24.2% mean body weight loss. Direct efficacy comparisons with other agents cannot be made because head-to-head trials have not been conducted; differences in study populations, entry criteria, and protocols between trials prevent reliable cross-trial conclusions [5].
5.4 Glycemic Outcomes
Although the Phase 2 trial enrolled participants without diabetes, changes in fasting glucose and insulin resistance markers were reported as secondary outcomes. All active dose groups showed improvements in fasting glucose and insulin sensitivity metrics consistent with the weight loss observed. The glycemic safety of GCGR agonism — specifically, the concern that glucagon receptor activation could produce fasting hyperglycemia — was monitored carefully. No clinically meaningful increase in fasting blood glucose was observed in the active treatment groups, consistent with the hypothesis that concomitant GLP-1R-mediated glucagon suppression and improved insulin sensitivity offset any GCGR-driven hepatic glucose output [5].
5.5 Safety and Tolerability
| Adverse Event | Placebo | 1 mg | 4 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|
| Nausea | ~9% | ~22% | ~38% | ~42% | ~45% |
| Diarrhea | ~7% | ~20% | ~27% | ~31% | ~33% |
| Vomiting | ~2% | ~10% | ~15% | ~20% | ~24% |
| Constipation | ~4% | ~10% | ~12% | ~14% | ~16% |
| Injection site reaction | <5% | <5% | <5% | <5% | <5% |
The adverse event profile was dose-dependent and consistent with the broader GLP-1 receptor agonist class. Gastrointestinal adverse events were most common during dose escalation phases and generally decreased in frequency with continued treatment. No severe hypoglycemia was reported. Serious adverse events occurred at low rates comparable to placebo. No dose-limiting cardiac, renal, or hepatic signals were identified in the Phase 2 data [5].
5.6 Phase 3 Trial Data — TRIUMPH Program
The TRIUMPH (TRIple hormone receptor agoniUM for People with obesity or overweight) Phase 3 program encompasses multiple trials evaluating retatrutide across obesity, type 2 diabetes, osteoarthritis, sleep apnea, metabolic liver disease, and cardiovascular populations. The first two trials to report results were TRIUMPH-4 (December 2025) and TRIUMPH-1 (May 2026).
TRIUMPH-4 — Obesity with Knee Osteoarthritis (December 2025)
According to topline results reported by Eli Lilly in December 2025, TRIUMPH-4 was a 68-week, double-blind, placebo-controlled Phase 3 trial enrolling 445 adults with obesity or overweight and moderate-to-severe knee osteoarthritis, without diabetes. Lilly reported that both the 9 mg and 12 mg doses met all primary and key secondary endpoints. These results have not yet been published in a peer-reviewed journal as of this article’s last review date [6].
| Outcome | Placebo | 9 mg / week | 12 mg / week |
|---|---|---|---|
| Mean body weight change | — | — | −28.7% (~71.2 lbs) |
| WOMAC pain score reduction | — | ~75.8% | — |
| Complete knee pain freedom | — | ~1 in 8 participants | |
| Systolic blood pressure | — | — | −14.0 mmHg |
| LDL cholesterol | — | ~−20% | |
| Prediabetes reversal rate | — | ~72% | |
Lilly reported TRIUMPH-4 as the first Phase 3 trial in the TRIUMPH program to report results. The 12 mg dose arm reported a 28.7% mean weight reduction at 68 weeks. Cardiometabolic improvements — including reductions in non-HDL cholesterol, triglycerides, high-sensitivity C-reactive protein, and systolic blood pressure — were reported alongside the weight loss data [6].
TRIUMPH-1 — Pivotal Obesity Trial (May 2026)
According to topline results reported by Eli Lilly in May 2026, TRIUMPH-1 was a randomized, double-blind, placebo-controlled Phase 3 trial enrolling 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Three doses (4 mg, 9 mg, and 12 mg weekly) were evaluated over an 80-week primary treatment period, with an extension to 104 weeks in participants with BMI ≥35. These results have not yet been published in a peer-reviewed journal as of this article’s last review date [7].
| Dose Group | Mean Weight Change (80 wk) | Mean Weight Change (104 wk, BMI ≥35) | % Reaching BMI <30 |
|---|---|---|---|
| Placebo | −3.9% | — | — |
| 4 mg / week | −17.6% | — | — |
| 9 mg / week | −23.7% | — | — |
| 12 mg / week | −25.0% (~70.3 lbs) | −30.3% (~85.0 lbs) | 65.3% |
Lilly reported that at 80 weeks, 45.3% of participants in the 12 mg group achieved ≥30% total body weight loss, and 65.3% reached a BMI below 30 kg/m². Mean waist circumference reduction was 24.1 cm at the highest dose. In the 104-week extension (BMI ≥35 subgroup), the 12 mg group reached approximately 30.3% mean reduction. For context, weight loss of this magnitude is generally in the range reported for some bariatric surgical procedures, though direct comparisons between pharmacological trials and surgical cohort studies carry significant methodological limitations [7].
All three studied doses met both the primary endpoint (weight loss superiority versus placebo) and all key secondary endpoints including cardiometabolic markers. The Phase 3 safety profile at 80 weeks was consistent with Phase 2 findings: nausea (42.4%), diarrhea (32.0%), constipation (26.1%), and vomiting (25.3%) at the 12 mg dose, predominantly during dose escalation. Dysesthesia and urinary tract infections were reported in approximately one in ten participants at the highest doses but were generally mild-to-moderate and resolved during treatment [7].
6. Evidence Status
The following table summarizes the current state of the retatrutide evidence base across the major stages of clinical development as of this article’s last review date.
| Evidence Type | Current Status |
|---|---|
| Phase 1b (T2D, PK/PD) | Published (Urva et al., 2022 — The Lancet) |
| Phase 2 (Obesity, dose-ranging) | Published (Jastreboff et al., 2023 — NEJM) |
| Phase 3 TRIUMPH (topline efficacy) | Topline results reported by Eli Lilly; peer-reviewed publication pending |
| Cardiovascular outcomes trial | Ongoing; results not yet available |
| Long-term safety surveillance | Ongoing; longest published follow-up is 80 weeks |
| Regulatory approval | Not yet approved as of this article’s last review date |
| Post-marketing surveillance | Not available |
What We Still Don’t Know
The following questions remain unanswered in the published literature as of this article’s last review date:
- Long-term cardiovascular outcomes: Whether retatrutide reduces MACE in high-risk populations has not been established. A dedicated cardiovascular outcomes trial has not reported results.
- Long-term pancreatic safety: Class-level concerns regarding GLP-1R agonism and pancreatic risk have not been evaluated beyond the Phase 3 trial windows.
- Chronic GCGR activation effects: The long-term metabolic, hepatic, bone, and renal consequences of sustained glucagon receptor agonism in humans have not been characterized.
- Weight regain after discontinuation: No published data exist on the trajectory of body weight after stopping retatrutide treatment.
- Performance in diverse populations: Phase 2 and Phase 3 data have limited representation of diverse racial, ethnic, and age-group populations.
- Regulatory timeline: Submission to and review by regulatory agencies had not been announced as of this article’s last review date.
7. Limitations of Current Research
The existing published research on retatrutide, while promising, carries several important limitations that constrain the conclusions that can currently be drawn from the data.
References
- Nauck MA, Meier JJ. "Incretin hormones: Their role in health and disease." Diabetes, Obesity and Metabolism. 2018;20(S1):5–21. doi:10.1111/dom.13129
- Frias JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
- Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon-, GIP-, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metabolism. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.08.004
- Urva S, Coskun T, Loh MT, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." The Lancet. 2022;400(10365):1869–1881. doi:10.1016/S0140-6736(22)02033-5
- Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
- Eli Lilly and Company. "Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press release, December 11, 2025. TRIUMPH-4 (NCT05959993). investor.lilly.com
- Eli Lilly and Company. "Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." Press release, May 2026. TRIUMPH-1. investor.lilly.com